Development of Fish Oil Based Gel for Drug Delivery System to Prevent Capsular Contracture

Background: Capsular contracture remains a formidable obstacle in the field of cosmetic and reconstructive breast surgery, leading to increased patient morbidity and the need for surgical revision. Traditional interventions have shown limited efficacy, prompting the exploration of new avenues for prevention and treatment. The development of NE-ω3-gel represents a breakthrough approach, leveraging the anti-inflammatory and anti-fibrotic properties of omega-3 fatty acids encapsulated within a nanoemulsion gel to address this issue head-on.

Methods: The comprehensive study methodology encompassed the synthesis, characterization, and application of NE-ω3-gel. Initial phases involved rigorous assessment of the gel's thermoreversibility, particle size distribution, and drug release properties to ensure optimal delivery and efficacy. The experimental design included thirty female Wistar Hannover GALAST M type rats, divided into three groups to evaluate the gel's performance against controls. These groups included a standard control, a positive control receiving direct fish oil supplementation, and an experimental group with breast implants coated in NE-ω3-gel. The study extended beyond physical and chemical assessments to include histological examinations and gene expression analysis, providing a holistic view of the gel's impact on preventing capsular contracture.

Results: Findings from this study were profound. NE-ω3-gel demonstrated exceptional thermoreversibility and a consistent particle size, suggesting its stability and reliability as a delivery system. Most notably, the application of NE-ω3-gel significantly mitigated the development of capsular contracture in the experimental group. This was evidenced by substantial reductions in capsular thickness, fibrosis, and the proliferation of myofibroblasts, which are key contributors to the contracture process. Furthermore, gene expression analysis revealed a favorable shift in inflammatory and fibrotic markers, with an increase in IFN-γ and decreases in IL-4 and TGF-β2, highlighting the gel's potent anti-inflammatory and anti-fibrotic effects.

Conclusion: The exploration of NE-ω3-gel in this study illuminates its potential as a revolutionary intervention for the prevention of capsular contracture post-breast implant surgery. By significantly impacting the physiological processes underlying capsular contracture, the NE-ω3-gel offers a promising solution to a longstanding problem in breast surgery. Its unique attributes, including thermoreversibility, particle size stability, and efficient drug delivery, position NE-ω3-gel as a viable and effective treatment option. The implications of this research are far-reaching, providing a foundation for further clinical trials and the potential integration of NE-ω3-gel into standard postoperative care, ultimately aiming to enhance patient outcomes and satisfaction in breast implant procedures. This study not only contributes to the scientific community's understanding of capsular contracture but also opens new pathways for innovative treatment approaches in the field of cosmetic and reconstructive surgery.

Breast

PSTM 2024